JLE

Journal de Pharmacie Clinique

MENU

Cost study of 8 peripheral blood stem cells autologous transplantation in non-Hodgkin’s lymphoma Volume 18, issue 4, Décembre 1999

Figures

See all figures

Authors
Service de pharmacie, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10.

Peripheral blood stem cells autologous transplantation (PBSCT) was now widely used to treat lymphomas and will certainly be a new therapeutic strategy in the next years. The objective of this study, realised in an hematology unit of Hospital Saint-Louis, was to evaluate the total cost of the type of transplantation. In this retrospective study, we analysed 8 patients treated for a non-Hodgkin’s lymphoma (NHL) between December 1993 and February 1995. We collected the data from the induction chemotherapy cycles (followed by cytapheresis) to the end of the autograft hospitalisation. Average number of days hospitalisation was 7.25 days (2-19) for the chemotherapy and 22 days (17-43) for the autograft. The cost per day of hospitalisation is 3,703.6 FF. The mean total cost for the NHL was 213,807 FF : 109,256 FF (51.1%) for hospitalisation, 44,192 FF (20.7%) for drugs, 23,702 FF (11.1%) for transfusions, 19,013 FF (8.9%) for cytapheresis, 10,315 FF (4.8%) for diagnostic tests and TBI 7,330 FF (3.4%). The haematopoietic growth factor represent 9% (5-14) of the total expenses and 47% (30-62) of the drugs. In different health care systems, north-americain or european, analyses with patients treated by PBPC, show that global costs changed between 13,325 $ (79,950 FF) to 48,300 $ (289,800 FF).